Manufacturing Round-Up: Dr Reddy’s Receives Form 483 With Five Observations

As firms including Laurus Labs, Natco and Strides get GMP compliance nods, the FDA has pulled up Dr Reddy’s for GMP compliance issues. Meanwhile, Numaferm has struck a licensing deal and Olon has started constructing a new plant.

Pharmacy_Laboratory
Several generics companies meet GMP standards as Dr Reddy’s receives a Form 483 • Source: Shutterstock

A recent audit of Dr. Reddy's active pharmaceutical ingredient manufacturing plant at Hyderabad, India by the US Food and Drug Administration has led the agency to issue a ‘Form 483’ with five observations. The company has responded saying they “will address the observations comprehensively within the stipulated timeline.”

For Dr Reddy’s, the good manufacturing practice compliance issues come at a time when they have recently become eligible for...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Manufacturing

More from Business